Press Releases

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin produced by C.

SALT LAKE CITY and SUNNYVALE, Calif., Oct. 21, 2024 /PRNewswire/ -- Recursion, a leading TechBio company decoding biology to radically improve lives, and Google Cloud today announced an expanded collaboration leveraging Google Cloud's technologies to support Recursion's drug discovery platform.

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY , Sept.

SALT LAKE CITY , Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place

Operational complementarities expected to yield annual synergies of approximately $100 million Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading

Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities Recursion expects 7 clinical trial readouts for itself over the next 18 months and approximately 10 clinical

Salt Lake City , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024 , before the opening of the

Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT Salt Lake City , Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates

Salt Lake City , June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its